Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Johnson and Johnson
Medtronic
McKinsey
Harvard Business School

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for UDP-alpha-D-glucuronic acid

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for UDP-alpha-D-glucuronic acid?

UDP-alpha-D-glucuronic acid is an investigational drug.

There have been 5 clinical trials for UDP-alpha-D-glucuronic acid. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2007.

The most common disease conditions in clinical trials are Muscular Diseases, Distal Myopathies, and Hepatitis. The leading clinical trial sponsors are National Human Genome Research Institute (NHGRI), University of Aarhus, and Therapeutics for Rare and Neglected Diseases (TRND).

Recent Clinical Trials for UDP-alpha-D-glucuronic acid
TitleSponsorPhase
Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)National Center for Advancing Translational Science (NCATS)Phase 1
Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)Therapeutics for Rare and Neglected Diseases (TRND)Phase 1
Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)National Human Genome Research Institute (NHGRI)Phase 1

See all UDP-alpha-D-glucuronic acid clinical trials

Clinical Trial Summary for UDP-alpha-D-glucuronic acid

Top disease conditions for UDP-alpha-D-glucuronic acid
Top clinical trial sponsors for UDP-alpha-D-glucuronic acid

See all UDP-alpha-D-glucuronic acid clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Merck
Baxter
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.